Form 4: Vera Therapeutics Exec Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Vera Therapeutics President and CEO Marshall Fordyce sold a significant number of Class A Common Stock shares under a pre-arranged trading plan.
Summary
- Marshall Fordyce, President and CEO of Vera Therapeutics, Inc., reported the sale of Class A Common Stock on May 12, 2026.
- The sales were executed under a written trading plan adopted on January 9, 2026, which complies with Rule 10b5-1(c) requirements.
- A total of 14,219 shares were sold at a weighted-average price of $36.6396, with individual sale prices ranging from $35.96 to $36.94.
- An additional 4,281 shares were sold at a weighted-average price of $37.0868, with individual sale prices ranging from $36.97 to $37.15.
- Following these transactions, Fordyce beneficially owns 122,949 shares directly and 99,081 shares indirectly through a GRAT and a Trust.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this filing neutrally to slightly negatively due to the executive selling shares, despite the transaction being conducted under a pre-approved 10b5-1 plan.
Negatives
- Company executive sold a notable number of shares, which could be perceived negatively by the market, although executed under a 10b5-1 plan.
Risks
- The sales were made under a Rule 10b5-1(c) plan, indicating a pre-determined strategy for stock transactions, which mitigates insider trading concerns but still represents a reduction in executive holdings.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on past transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1(c) plan by Vera Therapeutics' CEO is a common practice to allow executives to trade company stock systematically without facing accusations of insider trading, especially during periods of blackout restrictions or when diversifying their personal portfolios.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | Adoption of a written trading plan by the CEO, Marshall Fordyce, compliant with Rule 10b5-1(c). | 01/09/2026 | Enhances corporate governance by providing a structured and transparent method for insider stock transactions, mitigating potential insider trading concerns. |
Stakeholder Impact
- Shareholders may view the executive's stock sale with caution, although the 10b5-1 plan structure aims to alleviate concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 01/09/2026 | Date the written trading plan was adopted. |
| 05/12/2026 | Date of the reported stock transactions. |
| 05/13/2026 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Vera Therapeutics, VERA, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Marshall Fordyce, Class A Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.